LCM
PLX icon

Laurion Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Laurion Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42,813
Closed -$191K – 902
2021
Q1 		$191K Buy
+42,813
New +$199K ﹤0.01% 702

Other funds holding PLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Laurion Capital Management's PLX Position: Q2 2021 in Review

Laurion Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2021, closing a stake of 42,813 shares — an estimated $191K sold.

Laurion Capital Management first reported a position in PLX in Q1 2021 and held it in 1 quarter. The position peaked at $191K in Q1 2021. 33 funds tracked by Wall St. Rank hold PLX as of Q2 2021.

  • Laurion Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 42,813 Protalix BioTherapeutics shares in Q2 2021, an estimated $191K.
  • Laurion Capital Management first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 1 quarter.
  • Laurion Capital Management's Protalix BioTherapeutics position peaked at $191K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.